Condition: Ph+ ALL · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive · Sponsor: Ascentage Pharma Group Inc.
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
This description comes directly from the study's public registry record.
Ascentage Clinical Operations · 301-291-5658 · clinical-trials@ascentage.com
Always discuss trial participation with your own doctor first.
| Ascentage Investigative Site #1044 | Birmingham, Alabama, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1062 | Duarte, California, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1134 | Los Angeles, California, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1059 | Los Angeles, California, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1142 | Miami, Florida, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1045 | Augusta, Georgia, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1158 | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1069 | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1084 | Lexington, Kentucky, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1064 | Hackensack, New Jersey, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1098 | New Brunswick, New Jersey, United States | Not Yet Recruiting |
| Ascentage Investigative Site #1160 | Stony Brook, New York, United States | Not Yet Recruiting |
+ 78 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06051409